Roche presents new data for OCREVUS and fenebrutinib across broad patient populations at ECTRIMS 2025

Core Insights - Roche presents new data for OCREVUS and fenebrutinib at ECTRIMS 2025, highlighting significant advancements in multiple sclerosis treatment [1][2][3] Group 1: OCREVUS Efficacy and Safety - OCREVUS shows significant benefits in preventing disability progression in various MS patient groups, including children and pregnant women [2][3] - Phase III data confirm that OCREVUS maintains a consistent benefit-risk profile for up to two years, with near-complete suppression of relapses and disability progression [4][8] - In the ORATORIO-HAND study, OCREVUS demonstrated a 30% reduction in the risk of 12-week composite confirmed disability progression in advanced PPMS patients compared to placebo [6][9] Group 2: Fenebrutinib Development - Phase II data for fenebrutinib indicate near-complete suppression of disease activity at 96 weeks, with ongoing Phase III trials [14][15] - Fenebrutinib is designed to address unmet medical needs in MS by inhibiting both B-cell and microglia activation [19] Group 3: Pediatric and Pregnancy Outcomes - Data from the ocrelizumab pregnancy registry show no increased risk of adverse pregnancy or infant outcomes with OCREVUS exposure [10][11] - Infants exposed to OCREVUS during pregnancy or breastfeeding exhibited strong antibody responses to vaccines, indicating effective immune recognition [11][12] Group 4: Research and Development Focus - Roche is committed to advancing neuroscience research, with over a dozen medicines under investigation for neurological disorders, including multiple sclerosis [22][23]